Rheumatoid arthritis disease activity tends to improve during pregnancy, even when disease modifying agents are stopped. However, a minority of women with rheumatoid arthritis will continue to have active disease during pregnancy, and may require additional immunosuppression. Prior studies have yielded conflicting reports on the influence of active disease during pregnancy. Here, de Man et […]
While most observational studies have not demonstrated an increase in malignancy independently associated with TNF inhibitor use, a meta-analysis of short-term clinical trials data suggested an increase in malignancy risk occurring within months of initiating therapy with monoclonal antibodies directed against TNF-α (infliximab and adalimumab).
Initial combination therapy has been shown to be superior to step-up combination therapy in groups of RA patients; however, these findings are difficult to reconcile with the observation that many RA patients will have complete remission of disease on methotrexate alone. Practice patterns tend to emphasize initial treatment with methotrexate monotherapy, followed by the addition of other agents in combination for those with inadequate responses.
Tai Chi, a popular form of exercise involving stylized and controlled movements, has been advocated as a way to manage pain, maximize function, and improve quality of life for a variety of chronic musculoskeletal conditions, including osteoarthritis, rheumatoid arthritis, and fibromyalgia. However, the evaluation of its efficacy in these conditions has been limited by the […]
The U.S. Food and Drug Administration has approved the use of certolizumab pegol (which will be marketed under the trade name Cimzia) for the treatment of moderate to severe rheumatoid arthritis (RA). Certolizumab pegol is a novel TNF inhibitor comprised of an antigen-binding domain of a humanized TNF antibody coupled to polyethylene glycol (PEG) to […]